CN108156807A - 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 - Google Patents
含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 Download PDFInfo
- Publication number
- CN108156807A CN108156807A CN201680031203.4A CN201680031203A CN108156807A CN 108156807 A CN108156807 A CN 108156807A CN 201680031203 A CN201680031203 A CN 201680031203A CN 108156807 A CN108156807 A CN 108156807A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- rosuvastatin
- acceptable salt
- losartan
- amlodipine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110171819.4A CN112933093A (zh) | 2015-06-30 | 2016-06-29 | 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0093714 | 2015-06-30 | ||
KR20150093714 | 2015-06-30 | ||
PCT/KR2016/006977 WO2017003186A1 (en) | 2015-06-30 | 2016-06-29 | Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110171819.4A Division CN112933093A (zh) | 2015-06-30 | 2016-06-29 | 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108156807A true CN108156807A (zh) | 2018-06-12 |
Family
ID=57608904
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680031203.4A Pending CN108156807A (zh) | 2015-06-30 | 2016-06-29 | 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 |
CN202110171819.4A Pending CN112933093A (zh) | 2015-06-30 | 2016-06-29 | 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110171819.4A Pending CN112933093A (zh) | 2015-06-30 | 2016-06-29 | 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 |
Country Status (6)
Country | Link |
---|---|
KR (2) | KR20170003459A (ko) |
CN (2) | CN108156807A (ko) |
MX (2) | MX2017014311A (ko) |
PH (1) | PH12017501986A1 (ko) |
RU (1) | RU2724338C2 (ko) |
WO (1) | WO2017003186A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113747885A (zh) * | 2019-04-18 | 2021-12-03 | 韩美药品株式会社 | 包含依泽替米贝和氯沙坦的药物组合制剂 |
CN116018137A (zh) * | 2020-08-25 | 2023-04-25 | 株式会社大熊制药 | 用于治疗或预防高血压和高血脂症的单一剂型的药物组合物 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019022436A2 (ko) * | 2017-07-27 | 2019-01-31 | 에리슨제약(주) | Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물 |
KR20190043076A (ko) * | 2017-10-17 | 2019-04-25 | 한미약품 주식회사 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제 |
CN108245516B (zh) * | 2017-11-09 | 2019-04-12 | 浙江京新药业股份有限公司 | 一种含瑞舒伐他汀钙的药物组合物及其制备方法 |
CN109464407A (zh) * | 2018-12-27 | 2019-03-15 | 成都恒瑞制药有限公司 | 瑞舒伐他汀钙快速释放制剂及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1268053A (zh) * | 1997-08-29 | 2000-09-27 | 辉瑞大药厂 | 包含阿伐他汀和抗高血压药的联合疗法 |
US20030124191A1 (en) * | 2001-12-27 | 2003-07-03 | Jerome Besse | Use of an immediate-release powder in pharmaceutical and nutraceutical compositions |
CN101090718A (zh) * | 2004-12-30 | 2007-12-19 | 韩美药品株式会社 | 3-羟基-3-甲基戊二酰辅酶a还原酶抑制剂和抗高血压剂的复合剂型及其制备方法 |
US20100074951A1 (en) * | 2006-10-30 | 2010-03-25 | Hanall Pharmaceutical Company, Ltd. | Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors |
CN101690816A (zh) * | 2009-08-16 | 2010-04-07 | 王丽燕 | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 |
CN102292070A (zh) * | 2009-01-23 | 2011-12-21 | 韩美控股株式会社 | 具有提高的稳定性的包含氨氯地平和氯沙坦的固体药物组合物 |
WO2013154390A1 (en) * | 2012-04-13 | 2013-10-17 | Hanmi Pharm. Co., Ltd. | Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same |
WO2015080433A1 (en) * | 2013-11-29 | 2015-06-04 | Hanmi Pharm. Co., Ltd. | Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050096391A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and rosuvastatin |
WO2009154810A2 (en) * | 2008-02-25 | 2009-12-23 | Dr. Reddy's Laboratories Ltd. | Delivery systems for multiple active agents |
-
2016
- 2016-06-29 WO PCT/KR2016/006977 patent/WO2017003186A1/en active Application Filing
- 2016-06-29 MX MX2017014311A patent/MX2017014311A/es unknown
- 2016-06-29 RU RU2018103213A patent/RU2724338C2/ru active
- 2016-06-29 KR KR1020160081848A patent/KR20170003459A/ko active Application Filing
- 2016-06-29 CN CN201680031203.4A patent/CN108156807A/zh active Pending
- 2016-06-29 CN CN202110171819.4A patent/CN112933093A/zh active Pending
-
2017
- 2017-10-27 PH PH12017501986A patent/PH12017501986A1/en unknown
- 2017-11-08 MX MX2021005210A patent/MX2021005210A/es unknown
-
2018
- 2018-04-25 KR KR1020180047999A patent/KR20180044873A/ko not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1268053A (zh) * | 1997-08-29 | 2000-09-27 | 辉瑞大药厂 | 包含阿伐他汀和抗高血压药的联合疗法 |
US20030124191A1 (en) * | 2001-12-27 | 2003-07-03 | Jerome Besse | Use of an immediate-release powder in pharmaceutical and nutraceutical compositions |
CN101090718A (zh) * | 2004-12-30 | 2007-12-19 | 韩美药品株式会社 | 3-羟基-3-甲基戊二酰辅酶a还原酶抑制剂和抗高血压剂的复合剂型及其制备方法 |
US20100074951A1 (en) * | 2006-10-30 | 2010-03-25 | Hanall Pharmaceutical Company, Ltd. | Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors |
CN102292070A (zh) * | 2009-01-23 | 2011-12-21 | 韩美控股株式会社 | 具有提高的稳定性的包含氨氯地平和氯沙坦的固体药物组合物 |
CN101690816A (zh) * | 2009-08-16 | 2010-04-07 | 王丽燕 | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 |
WO2013154390A1 (en) * | 2012-04-13 | 2013-10-17 | Hanmi Pharm. Co., Ltd. | Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same |
WO2015080433A1 (en) * | 2013-11-29 | 2015-06-04 | Hanmi Pharm. Co., Ltd. | Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin |
Non-Patent Citations (1)
Title |
---|
李全林: "《新医药开发与研究 下册》", 31 December 2008, 中国医药科技出版社 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113747885A (zh) * | 2019-04-18 | 2021-12-03 | 韩美药品株式会社 | 包含依泽替米贝和氯沙坦的药物组合制剂 |
CN113747885B (zh) * | 2019-04-18 | 2023-08-15 | 韩美药品株式会社 | 包含依泽替米贝和氯沙坦的药物组合制剂 |
TWI827828B (zh) * | 2019-04-18 | 2024-01-01 | 南韓商韓美藥品股份有限公司 | 包含依澤替米貝(ezetimibe)及洛沙坦(losartan)之藥學組合製劑 |
CN116018137A (zh) * | 2020-08-25 | 2023-04-25 | 株式会社大熊制药 | 用于治疗或预防高血压和高血脂症的单一剂型的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
KR20170003459A (ko) | 2017-01-09 |
RU2018103213A (ru) | 2019-07-31 |
MX2021005210A (es) | 2021-06-18 |
PH12017501986A1 (en) | 2018-03-19 |
WO2017003186A1 (en) | 2017-01-05 |
KR20180044873A (ko) | 2018-05-03 |
CN112933093A (zh) | 2021-06-11 |
RU2724338C2 (ru) | 2020-06-23 |
RU2018103213A3 (ko) | 2019-12-09 |
MX2017014311A (es) | 2018-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108156807A (zh) | 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 | |
US20200375968A1 (en) | Apixaban formulations | |
TWI649099B (zh) | 包含氨氯地平(amlodipine)、洛沙坦(losartan)及羅舒伐他汀(rosuvastatin)之藥學組合物配方 | |
EP2413931B1 (en) | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same | |
CN101528203B (zh) | 用于基于择时治疗理论治疗心血管疾病的联合制剂 | |
RU2298418C2 (ru) | Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза) | |
MX2008016099A (es) | Composicion farmaceutica que comprende amlodipina y losartan. | |
CA2586760A1 (en) | Stabilized ramipril compositions and methods of making | |
EP3320903B1 (en) | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin | |
CN102335176B (zh) | 一种口服固体药用组合物及其制备方法 | |
CN108289850B (zh) | 含有氨氯地平、氯沙坦和氯噻酮的药物复合制剂 | |
CA2628955A1 (en) | Compositions of stabilized ramipril in combination with another active agent | |
CN103249415B (zh) | 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法 | |
JP4165224B2 (ja) | 発泡性組成物 | |
US20160045497A1 (en) | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor | |
CN102316856A (zh) | 药物制剂 | |
TWI827828B (zh) | 包含依澤替米貝(ezetimibe)及洛沙坦(losartan)之藥學組合製劑 | |
WO2024109927A1 (zh) | 包含美阿沙坦钾与钙通道阻滞剂的药物组合物,及其制备方法及应用 | |
TWI734046B (zh) | 包含替米沙坦或其藥學上可接受鹽類之具有改良的吸濕性質和溶解速率之製劑 | |
TW202432121A (zh) | 包含美阿沙坦鉀與鈣通道阻滯劑的藥物組合物、及其製備方法及用途 | |
BR112015022000B1 (pt) | Preparação de combinação farmacêutica, composição farmacêutica e uso da preparação de combinação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180612 |